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Somatostatin receptor scintigraphy (SRS) incorporates dual time-point imaging to differentiate 
pathological uptake by neuroendocrine tumours (NETs) from physiological activity. SPECT/CT 
improves accuracy allowing reliable distinction. Technetium-99m SRS (Tektrotyd) permits single-day 
imaging although dual time-point protocols are still recommended. The purpose of this study was to 
assess the feasibility and efficacy of a streamlined single time-point Tektrotyd SRS protocol. 
Methods and Materials 
Tektrotyd imaging in 50 consecutive patients with NETs was retrospectively reviewed. Imaging was 
independently assessed by two experienced reporters with dual-certification in Radiology & Nuclear 
Medicine and agreed in consensus. The presence of physiological bowel activity and/or further sites 
of equivocal uptake on 4-hour planar imaging and whether SPECT/CT assessment allowed accurate 
diagnosis was tabulated. A judgement was also made in each case on whether 2-hour planar imaging 
was necessary for accurate diagnostic interpretation.  
Results 
36 patients (72%) had positive findings on Tektrotyd SPECT/CT. 8 patients (16%) had bowel activity 
on 4-hour planar imaging which could be considered to have hampered interpretation without 
access to SPECT/CT. 11 studies in 10 patients (20%) demonstrated areas of indeterminate uptake on 
planar imaging; 5 in the uncinate process of the pancreas, 3 in the nasal cavity or paranasal sinuses, 
1 in the adrenal glands, 1 in a focus of inflammation on the posterior abdominal wall and 1 at the tip 
of a central venous line. In all cases, accurate interpretation of findings was possible with SPECT/CT, 
without the 2-hour planar image.  
Conclusion 
2-hour planar imaging could be safely omitted from Tektrotyd SRS incorporating SPECT/CT imaging 
without reducing accuracy of diagnostic interpretation. Streamlined imaging has the potential to 
reduce patient inconvenience and improve scanner and staff efficiency.  
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I   
Neuroendocrine tumours (NET) comprise a diverse group of malignancies that derive from 
embryonic neural crest cells of various organs such as the lungs, gastrointestinal tract, adrenal 
medulla, thyroid and pituitary gland [1,2]. They are known to over express somatostatin receptors, 
the presence of which, particularly subtypes 2 & 5, allows detection with radiolabelled peptide 
somatostatin analogues [3]. Since the introduction of these radionuclides, Somatostatin Receptor 
Scintigraphy (SRS) has been in widespread clinical use for assessment and staging of NETs [4]. More 
recently, development of highly specific positron emitting radiopharmaceuticals have allowed 
progress in detection of lesions using somatostatin receptor (SSR) PET-CT which is now considered 
the gold standard for initial staging, pre-curative surgery and investigation of unknown primaries [5]. 
However, despite the obvious strengths of SSR PET-CT, adoption into routine clinical practice in the 
UK has been slow due to a combination of financial and regulatory issues [6]. Consequently, SRS 
using Indium-111 (In-111) labelled radiopharmaceuticals has continued to be widely utilised for 
staging of neuroendocrine malignancies, with single photon emission computed tomography / 
computed tomography (SPECT/CT) fusion improving diagnostic assessment beyond that of 
traditional planar imaging.  
There are some limitations with In-111 SRS including the logistical constraints of supply of cyclotron-
produced radio-isotope and a 2-day imaging protocol. Recently a Technetium-99m (Tc99m) labelled 
Somatostatin analogue has become more widely available and this radiopharmaceutical overcomes 
some of the issues. Tc99m-HYNIC-Tyr3-Octreotide (Tektrotyd) has the advantage of ready availability 
of radio-isotope from departmental Technetium-99m generators, a single day imaging protocol and  
superior image resolution [7]. In addition the mean effective dose from Tc99m-Tektrotyd, reported 
to be 4.6 +/- 1.1mSv [8], is significantly less than that for In-111-Octreotide at 8-16 mSv [9] 
Prior studies of In-111 SRS have shown that integration of SPECT/CT facilitates streamlining of 
imaging protocols with reduction in imaging time-points needed as it permits more reliable 
differentiation of pathological uptake from physiological activity [5,10]. Widely adopted In-111 SRS 
protocols recommend image acquisition at 24 (+/- 48) hours’ post-injection allowing ‘wash-out’ of 
accumulated bowel uptake of excreted tracer. 4-hour imaging is conducted in some centres, aimed 
to image prior to bowel accumulation but this advantage is often offset by higher background 
activity levels [11,12]. 
Standard imaging protocols for Tc99m-Tektrotyd include a 2-hour whole body planar acquisition 
with the aim to obtain images prior to uptake in the bowel and biliary tree, followed by 4-hour 
whole body planar imaging and SPECT/CT through the abdomen +/- thorax [13–15].  
The aim of this study was to review initial experience with Tc99m-Tektrotyd in a large tertiary 
referral centre and to determine the feasibility of single-time-point SRS with SPECT/CT as a 
replacement for dual time-point imaging. The hypothesis was that SPECT/CT should distinguish 
between pathological and physiological uptake at 4 hours’ post injection rendering the 2-hour 
acquisition unnecessary. A single-time point acquisition would allow streamlining of services and be 
even more patient friendly. 
  
Materials and methods 
Patient selection 
Following adoption of a new SRS protocol using Tc99m-Tektrotyd in place of In-111 DTPA-Octreotide 
at a large tertiary referral centre in December 2016, data from 50 consecutive patients with 
suspected / confirmed NET, or undergoing post-surgical surveillance of a resected NET was collated 
prospectively. Our institution does not require formal ethics committee approval or written patient 
consent for retrospective service evaluation studies such as this. The study was registered, received 
approval and was added to the Institutional Clinical Audit database. 
Imaging protocol 
After IV administration of 600 – 740 MBq of Tc99m-Tektrotyd, planar whole body images were 
acquired at 2 and 4 hours post injection, supplemented with abdominal +/- thoracic SPECT/CT 
imaging at 4 hours. The decision for inclusion of a head and neck or thoracic SPECT/CT acquisition 
was based on provided clinical information and appearances of the 2-hour planar imaging. 
Whole body planar images, from skull vertex to mid-thigh, were acquired in anterior and posterior 
projections on a dual-head gamma camera with low-energy, high resolution collimators (Discovery 
670, GE Healthcare, Amersham, UK); using a 20% energy window centred at 140.5 keV and a table 
speed of 6 cm per minute. SPECT/CT images were obtained on the same hybrid gamma camera. The 
SPECT portion of the acquisition was acquired in a 360-degree orbit with 30 steps per head (20 
s/stop) resulting in a total of 60 projections, and processed using ordered subset expectation 
maximization (OSEM) iterative reconstruction (2 sets, 10 subsets) into a 128 x 128 matrix. At our 
institution a total of 60 projections is obtained as a compromise between the highest SPECT image 
resolution achievable and acquisition duration aimed at minimising patient motion which would 
otherwise necessitate movement correction and associated artefact. CT-based attenuation 
correction was applied to the SPECT data.  
As per departmental protocol, a non-contrast enhanced CT acquisition was obtained using a low-
dose technique (helical acquisition, 120kVp, Smart mA from 30 – 150mAs) with images 
reconstructed at a slice thickness of 2.5 mm in a 512 x 512 matrix. CT data was reconstructed using 
proprietary Adaptive Statistical Iterative Reconstruction [ASiR] (GE Healthcare) using an ASiR 
processing level of 40%. Median dose-length product (DLP) for all studies was 116.3 mGy/cm (range 
39.4 – 833). Table 1 illustrates the minimum, maximum, median and mean DLP values for head and 
neck, thorax, abdomen and total study acquisitions. 
Image interpretation 
Tc99m-Tektrotyd planar, SPECT and SPECT/CT images were viewed on a diagnostic workstation 
[Xeleris Version 3.0, GE Healthcare, Amersham, UK]. This allows viewing of planar images as well as 
SPECT and CT data individually and fusion of modalities. CT components of each SPECT/CT study 
were also viewed on a diagnostic PACS workstation [Agfa IMPAX, Version 5.6, Agfa Healthcare, 
Belgium]. 
Two dual-qualified consultants in radiology and nuclear medicine with a minimum of 8 years’ 
experience of reporting SRS studies, independently reviewed images whilst unaware of clinical 
findings, other diagnostic imaging results or the final histological diagnosis. Each reader assessed the 
presence or absence of physiological bowel activity and/or further sites of equivocal uptake on 4-
hour planar imaging and whether SPECT/CT assessment allowed accurate diagnosis, results were 
tabulated. True positive findings were considered to be those with uptake secondary to disease and 
not inflammatory or physiological activity. A judgement was also made in each case on whether 2-
hour planar imaging was necessary for accurate diagnostic interpretation. Any disagreements were 
discussed and agreed in consensus. 
  
 
Between December 2016 and June 2017, 50 consecutive patients (19 male, 31 female; mean age: 61 
years; range 30-84 years) underwent Tc99m-Tektroytd SRS: 26 patients had a 
gastroenteropancreatic NET, 3 had a thoracic NET, 2 had a suspected head & neck NET, 7 patients 
had an unknown primary (5 with hepatic NET metastases, 2 with carcinoid syndrome) and 12 
underwent SRS for re-assessment following previously resected NETs. 
Prior to consensus review both observers identified identical cases demonstrating true positive 
findings and cases showing physiological bowel uptake that could hamper planar imaging 
interpretation. There were six cases identified by both observers with areas of extra-intestinal 
indeterminate activity on planar imaging and four further cases noted by Observer 1 (Figure 1). The 
four discordant cases were reviewed in consensus by both observers and following discussion all 
were felt to show additional activity that could be considered indeterminate on 4-hour planar 
imaging. 
36/50 (72%) patients had true positive findings on SRS. 8/50 (16%) had bowel activity on the 4-hour 
planar image that could be considered to have hampered interpretation in the absence of SPECT/CT 
(Table 2). 
As an example; in patient 4, pathological uptake in the pelvis could potentially have been 
misinterpreted as physiological bowel activity however the SPECT/CT acquisition clearly localised 
activity to peritoneal disease (Figure 2). Utilisation of a dual-phase planar only imaging protocol in 
this case may have missed this pathology as activity was slightly reduced on the 2-hour image. The 
lack of a 2-hour image in this study would not have adversely affected imaging interpretation. 
10/50 studies (20%) demonstrated areas of indeterminate uptake on planar imaging in addition to 
that in the bowel; in four cases this was attributable to prominent uptake in the uncinate process of 
the pancreas. In one example with no tracer-avid pathology (patient 8), there was a relative increase 
in activity in the uncinate process of the pancreas on the 4-hour image when compared with the 2-
hour planar study (Figure 3A & 3B); this potential abnormality was more reliably convincing of 
physiological uptake on the SPECT/CT acquisition given a lack of an abnormality on the CT 
component (Figure 3C) or prior contrast-enhanced CT (not shown). In this case, planar imaging also 
demonstrated diffuse bowel-related tracer uptake for which the 2-hour image was helpful in adding 
confidence for the bowel activity being physiological. The SPECT/CT acquisition however allowed 
greater confidence in accurate image interpretation than the 2-hour planar image. 
Patients 25 and 28 also had prominent uptake in the region of the uncinate process potentially 
hampering interpretation. In the former, the 2-hour image was not helpful and in the latter, the 
SPECT/CT provided more convincing evidence of a physiological aetiology. 
In all cases, the combination of 4-hour planar imaging and SPECT/CT permitted confident image 
interpretation without 2-hour imaging.  In two cases the 2-hour planar views would have potentially 
been helpful but in both instances SPECT/CT was more definitive. As an example, Patient 49, a 59-
year-old male with a history of previously resected midgut carcinoid tumour underwent Tc99m-
Tektrotyd SRS for characterisation of equivocal mesenteric nodes demonstrated on contrast 
enhanced CT. With the benefit of 2-hour planar imaging, a lesion blending with physiological bowel 
activity on the 4-hour image becomes appreciable. However, the subsequent SPECT/CT guided 
confident diagnosis of a distal ileal NET (Figure 4). 
  
 
This study aimed to determine the feasibility of a streamlined imaging protocol in Tc99m-Tektrotyd 
SRS SPECT/CT with omission of 2-hour planar imaging, which, to the best of our knowledge has not 
been previously reported. Two prior studies have reported that use of SPECT/CT in In-111-labelled 
SRS allows rationalisation of dual time-point imaging to a single time-point protocol without 
impairment of diagnostic ability [5,10]. Our rationale for switching from In-111 SRS to Tc99m-
Tektrotyd imaging of NETs included the superior image resolution afforded by the physical 
characteristics of Tc99m which make it better suited to gamma camera imaging, lower patient 
radiation exposure and increased availability of tracer from departmental generators permitting 
more flexibility in departmental workflow [7]. A national survey of CT doses in hybrid imaging which 
obtained data from 43 SPECT/CT systems across the UK reported a median DLP from Octreotide 
studies of 152 mGy/cm (range 43-907) and suggested a national diagnostic reference level for 
Octreotide SPECT-/CT of 240 mGy/cm, the median DRL in this series was well within that 
recommended limit (116 mGy/cm) [16]. Tc99m-Tektrotyd has been in clinical use in Eastern 
European countries for over a decade but has only become commercially available in the UK more 
recently. 
The implementation of a new Tc99m-Tektrotyd based SRS + SPECT/CT protocol in our department 
from December 2016 allowed patients to undertake their examination during a single day rather 
than having to return the next day for additional imaging at 24 hours after injection with In-111 SRS. 
Gabriel et al reported a higher sensitivity for Tc99m-Tektrotyd in an early intra-patient comparison 
study with In-111 SRS in a cohort of 41 patients with NETs before the widespread introduction of 
SPECT/CT [17]. In their series 2 patients (5%) had false positive findings on Tc-99m Tektrotyd SRS due 
to non-specific tracer accumulation and for this reason additional early scanning at 1-2 hours was 
advocated [17].  Co-registration of SPECT and separate diagnostic CT was subsequently reported to 
reduce false positive results [18]. In our patient cohort, ten patients (20%) demonstrated areas of 
indeterminate uptake on planar imaging; in five cases this was attributable to prominent uptake in 
the uncinate process of the pancreas. Findings at integrated SPECT/CT and/or prior contrast 
enhanced imaging, specifically the absence of a focal lesion on anatomical imaging, surpassed the 
ability of the 2-hour study in aiding interpretation. Uncinate process activity is a well-known 
physiological appearance in SRS, occurring as a result of physiological peptide uptake [18-20] and 
awareness of this normal variant should allow confident interpretation with the benefit of a 4-hour 
planar image and SPECT/CT acquisition. 
There were eight cases (16%) in which bowel activity could potentially have hampered interpretation 
on planar imaging analysis alone. In one example, pathology which could feasibly have been 
mistaken for physiological bowel activity on the 4-hour planar image was clearly identified as 
peritoneal disease on SPECT/CT. SPECT/CT permitted a confident diagnosis of physiological bowel 
uptake in instances of equivocal upper abdominal activity, as in the case described. In cases where 
there is clinical concern for head & neck or thoracic disease or whole body planar imaging reveals 
indeterminate head & neck or thoracic uptake, SPECT/CT of the corresponding region is included as 
per departmental protocol. 
Pooled sensitivity (93%) and specificity (96%) for Gallium-68 labelled SSR PET-CT exceeds SRS 
SPECT/CT detection rates for NETs [22]. For this reason, SSR PET-CT has been widely adopted into 
routine clinical practice in many countries. Unfortunately, despite SSR PET-CT being on the list of 
indications funded by NHS England there is limited availability in the UK at present with only a few 
highly-specialised centres able to provide this imaging technique. It is hoped that this technology will 
become more widely available in the next few years. 
There are limitations to this study including the relatively small cohort size, retrospective nature and 
lack of definitive histological confirmation of findings. Despite these shortcomings, the study 
suggests that 2-hour planar imaging could be safely omitted from Tc99m-Tektroytd SPECT/CT 
imaging protocols without reducing confidence in diagnostic interpretation. This not only allows 
streamlining of camera and staff time but also reduces patient discomfort and potentially improves 
their experience during their time in the nuclear medicine department. 
 
2-hour planar imaging could be safely omitted from Tektrotyd SRS incorporating SPECT/CT imaging 
without reducing accuracy of diagnostic interpretation. Streamlined imaging has the potential to 
reduce patient inconvenience and improve scanner and staff efficiency.  
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Figures & Tables 
 
FIGURE 1 Observer variability prior to consensus discussion for (A) true positive activity (B) 4-hour 
planar bowel activity potentially hampering planar interpretation and (C) sites of indeterminate 





FIGURE 2 Tc99m-Tektrotyd (A) 2-hour and (B) 4-hour planar imaging (C) non-contrast CT and (D) 
fused images from a subsequent SPECT/CT acquisition through the pelvis. Tracer uptake within a 
focus of peritoneal recurrence (white and yellow arrows) which could be mistaken for physiological 
bowel uptake on planar whole-body imaging (arrow heads). 
 
  
FIGURE 3 Tc99m-Tektrotyd planar whole-body anterior (A) 2-hour and (B) 4-hour images 
demonstrate focal uptake in the region of the central upper abdomen of increased prominence on 
the delayed study (black arrow and arrow-head). Axial (C) SPECT/CT fusion images at 4 hours clearly 
showing the central upper abdominal activity localising to a morphologically normal pancreatic 
uncinate process (white arrow) in keeping with physiological polypeptide tracer uptake. 
 
FIGURE 4 Tc99m-Tektrotyd (A) 2-hour and (B) 4-hour planar imaging, (C) coronal fused SPECT/CT 
image and (D) fused 3D reconstruction. A focus of equivocal tracer activity on 4-hour planar imaging 
(black arrow head) which should be interpreted as pathological with appreciation of its persistence 
from the 2-hour image (black arrow). The subsequent SPECT/CT clearly demonstrates pathological 
uptake in a primary distal ileum NET (red cross hairs). 
 
  
TABLE 1 Dose Length Product (DLP) minimum, maximum, median and mean values for abdominal, 
thoracic, head/neck and total study CT acquisitions. 
 Abdomen Thorax Head & Neck Total study 
Number of studies  50 7 2 50 
Minimum DLP (mGy-cm) 39.4 22.3 21.0 39.4 
Maximum DLP (mGy-cm) 607.1 169.9 356.0 833.0 
Median DLP (mGy-cm) 115.5 70.8 188.5 116.3 
Mean DLP (mGy-cm) 161.1 77.5 188.5 180.1 
 
  
TABLE 2 Assessment of Tc99m-Tektrotyd studies for presence of bowel activity on 4-hour imaging 
hampering interpretation, sites of indeterminate uptake and the ability to confidently diagnose 





Bowel activity hampering 
interpretation on 4-hour planar 
imaging 
Sites of Indeterminate 
uptake on 4-hour 
planar imaging 
2-hour images 
necessary for correct 
interpretation? 
1 + - - - 
2 - - Paranasal sinuses - 
3 + - - - 
4 + + - - 
5 + - - - 
6 + - - - 
7 + - - - 
8 - - Uncinate process - 
9 + - - - 
10 + - - - 
11 - - Hickman Line - 
12 - - - - 
13 + - - - 
14 + - - - 
15 + + - - 
16 - - - - 
17 + + - - 
18 + - Adrenal glands and 
uncinate process 
- 
19 + - - - 
20 + - - - 
21 - - - - 
22 + - - - 
23 - - - - 




25 + - Uncinate process - 
26 + + - - 
27 + - - - 
28 + - Uncinate process - 
29 - - - - 
30 - - - - 
31 - - - - 
32 + - - - 
33 + - - - 
34 + - - - 
35 + - - - 
36 + - - - 
37 + - - - 
38 + + - - 
39 + + - - 
40 + - - - 
41 - - - - 
42 - - Nasal mucosa - 
43 + - - - 
44 + - - - 
45 + - - - 
46 - - Nasal mucosa - 
47 - - - - 
48 + + Uncinate process - 
49 + + - - 
50 + - - - 
 
